RxDoctor Payments Data

Deborah McCoy, MD

Internal Medicine · Houston, TXNPI 1649387002

Payments from drug & device makers

$4,308in general payments, 2019–2025

Across 195 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$566
  • Bayer$447
  • Akebia Therapeutics Inc$438
  • Otsuka America Pharmaceutical, Inc.$403
  • Lilly USA, LLC$368
  • AstraZeneca$356
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,308 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$43,906
Medicare patients
165
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$38,806
FarxigaDapagliflozin Propanediol33$23,712
JanuviaSitagliptin Phosphate23$23,351
JardianceEmpagliflozin20$23,127
EliquisApixaban15$12,866
OzempicSemaglutide11$12,298
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,753
Atorvastatin Calcium128$1,352
Albuterol Sulfate HfaAlbuterol Sulfate14$780
Nifedipine ErNifedipine22$764
Gabapentin32$726
Metoprolol Succinate57$666
Valsartan24$659
Pravastatin Sodium16$525
Amlodipine Besylate98$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$368$38,80633 claims
AstraZenecaFarxiga$356$23,71233 claims
MerckJanuvia$26$23,35123 claims
Boehringer IngelheimJardiance$78$23,12720 claims
PfizerEliquis$23$12,86615 claims
Novo NordiskOzempic$205$12,29811 claims
ANI Pharmaceuticals, Inc.Valsartan$235$65924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →